All In Nutritionals
Facebook Instagram Linkedin Twitter Website
Home Blog Page 271

Probiotics Reduce Skin Sensitivity in Babies – May Prevent Future Problems

By
Editor
-
0

The probiotic strains used in GENESTRA HMF Baby B and HMF Baby F probiotic formulas were evaluated in a recent clinical trial.

Key findings from the 2014 placebo-controlled clinical trial conducted by Allen et al. showed that probiotic supplementation in babies from birth to 6 months reduced skin prick sensitivity to common food allergens by 44 percent and reduced atopic eczema by 57 percent.
Additionally, a 2010 safety study conducted by Allen et al., found that the usage of these probiotic strains did not increase adverse event incidence, number of visits to the doctor, and did not have a negative impact on mothers’ assessment of infant health. Based on these findings, the authors concluded that usage of the probiotic formula was safe during early infancy.

“A healthy gut flora plays an important role in early immune stimulation, and variations in gut colonization at early ages have been associated with the development of atopic disease such as eczema,” said Dr. Nigel Plummer, key research contributor at GENESTRA BRANDS. “Our new HMF Baby probiotic supplements support early colonization of bacteria in an infant’s gut to reduce incidence of skin sensitivity.”

According to the Canadian Dermatology Association, it is estimated that up to 17 percent of Canadians suffer from Atopic Dermatitis at some point in their lives, and it usually starts in infants and young children. HMF Baby B and HMF Baby F both provide Lactobacillus and Bifidobacterium – two of the most common categories of probiotic bacteria that tend to be lower in infants with atopic dermatitis or skin sensitivity.

HMF probiotics are proprietary, non-pathogenic, human-sourced microflora bacterial strains that exhibit strong epithelial adherence and a naturally high tolerance to stomach acid. The HMF Baby supplements are available in a powder format that dissolves easily into breast milk, formula or water and are free of gluten and soy.

22 pharmacies across BC selected for first-ever genomics project

By
Editor
-
0

Twenty-two pharmacies in rural and urban locations across British Columbia have been selected to participate in a research project that aims to help bring personalized medicine to patients through community pharmacists.


The “Genomics for Precision Drug Therapy in the Community Pharmacy” project is the first of its kind in North America. It is funded by the BC Pharmacy Association (BCPhA) and Genome BC, with research done by a team at the University of British Columbia’s Faculty of Pharmaceutical Sciences.


The research project focuses on using community pharmacists to collect saliva samples to test how an individual’s DNA can impact medication selection and dosage. The project will develop standard operating procedures for the collection of patient saliva samples by community pharmacists as well as procedures for the processing and sequencing of the DNA in these samples by UBC researchers.


Across the province, the 22 pharmacies will recruit 200 volunteer patients, who are currently taking the anticoagulation drug warfarin, to be part of the study. Researchers will do a retrospective analysis of DNA information to learn how genetics would have altered the drug dosage patients were prescribed.


Pharmacy locations include Burnaby, Courtenay, Cranbrook, Enderby, Fort St John, Hope, Houston, Kamloops, Kelowna, Penticton, Port Coquitlam, Port McNeill, Prince George, Surrey, Vancouver, Victoria and Williams Lake.


“Pharmacists, who are experts in medication, are the health-care practitioners best positioned to collect and use patient genetic information to help make medication selection and dosing decisions,” said Geraldine Vance, CEO of the BC Pharmacy Association.


“Over time, the aim is to use DNA to make decisions about the most commonly-prescribed medications, making personalized medicine accessible for all patients in the province.”


There are more than 1,200 community pharmacies across the province, meaning any British Columbian could ultimately have access to this testing regardless of where they live.


“With the modern genome technology used in this project, the idea of personalized medicine can become a reality,” said UBC lead researcher Dr. Corey Nislow.


“We know there are more than 150 medications that are impacted by an individual’s DNA. This project is about using that genetic information to make decisions about which medications are right for a patient – the right drug, in the right dosage at the right time.”

Omega-3 Joy Reaches China

By
Editor
-
0

On March 24th, Neptune announced that the Chinese Patent Office has granted Acasti a composition and use patent – valid until 2030 – relating to concentrated therapeutic phospholipid omega-3 compositions and covering methods for treating or preventing diseases associated with cardiovascular diseases, metabolic syndrome, inflammation, neurodevelopmental diseases, and neurodegenerative diseases. “To date, Acasti has received patents in the United States, Australia, Panama and South Africa for its phospholipid composition,” highlighted Benoit Huart, Director Legal Affairs at Acasti. “As well, similar patent applications are pending in more than 40 jurisdictions worldwide and are actively being pursued. This is yet another example of our commitment to build and extend our patent estate.”


“Today’s announcement further enhances the value of our intellectual property, by protecting a vast market and providing potential expansion opportunities for Acasti’s products going forward,” said Pierre Lemieux, PhD, Acasti’s Chief Operating Officer. “There is a large unmet need for high-quality, well-studied and differentiated krill products in China. It is the third largest pharmaceutical market in the world, with an average compound annual sales growth rate of approximately 20% over the past ten years.”

Cannabigerol (CBGa) Biosynthesis Overview

By
Editor
-
0

Naturally Splendid Enterprises is currently identifying multiple opportunities emerging from the recently acquired access to technologies from FSL Laboratories (FSL).


Naturally Splendid CEO Craig Goodwin reports, “One of the opportunities in front of us is the potential to biosynthetically produce pharmaceutical grade cannabinoids without having to grow a single plant and thus potentially lowering the cost of production significantly, creating a competitive advantage over traditional extraction and formulation technologies. This technology may be applied in the development of food, beverage and nutraceutical/cosmetic products and eventually for pharmaceutical applications.”


Naturally Splendid VP of Operations Bryan Carson reports, “There is no better way to advance these opportunities than to retain key personal within Boreal to assist us in driving multiple revenue opportunities. This is further proof of the existing and in fact, the continued strengthening of the relationship between FSL / Boreal and Naturally Splendid.”


Ms. Katie Schmitt, from Boreal Technologies will be directly involved in the transfer of technological expertise obtained under the agreement from FSL and implementation of commercialization strategies.


She reports, “FSL has filed a patent application covering the organic and enzymatic synthesis of cannabinoids. This technology will allow for industrial scale production of cannabinoids catalyzed from Cannbigerolic acid (CBGa) without the requirement to grow large quantities of plants. The process mimics the natural synthesis that occurs in the plant’s bio-pathway. Cannabinoids produced in the bioreactor are pharmaceutical grade purity (>99%) and devoid of by-products and impurities. The largest advantages with this technology over existing methods of cannabinoid production (natural and synthetic) are: its low price per unit manufacturing costs (potentially 1/10th to 1/3rd the cost of existing methods); its ability to produce a diversity of products from a single manufacturing line; and commercial scalability. It also creates access to lesser known cannabinoids for research and analysis of their potential therapeutic applications.


NSP will identify licensed partners in legal jurisdictions that it can collaborate with to develop safe and efficacious cannabinoid therapies utilizing this technology. Potential therapeutic applications include: Analgesic to relieve pain; Antibacterial to slow bacterial growth; Anti-inflammatory to reduce inflammation systemically; and Anti-Proliferative – which may inhibit cancer cell growth through apoptosis.

When is an Apple Not an Apple?

By
Editor
-
0

A company called Okanagan Specialty Fruits (recently acquired by US Bio-technology firm, Intrexon) has just received Canadian and US approval for its genetically modified (GM) “non-browning” apple – it does not brown when you slice it, for 15 days or more. The company says the GM apples “have more eye appeal: no yucky browning” – but, according to the Canadian Biotechnology Action Network, (CBAN), sixty-nine per cent of Canadians don’t want it approved. Many groups representing fruit growers in Canada are also opposed. Consumer rejection and possible contamination from GM apples threatens the future of our apples, and the farmers who grow them. The apple will hit the market with two different varieties : Arctic granny and Arctic golden.


Lots of people who don’t object to the apple itself, believe strongly that the product should be labeled GM so consumers can make an informed choice.
Fred Steele, president of the BC Fruit Growers’ Association told the Penticton Western News, “I’m not arguing the science. But if (Health Canada) decided there’s no problem with it, then there should be no problem labelling it,” he said. “Let’s let the people decide. If it’s fine — fine. If it’s not, (consumers) will let them know.”


While scientific studies have not been able to identify any health risks, many pundits have said things like “how could a food that never goes bad possibly be good for you?”

New Canadian distributor of Pranarōm essential oil products

By
Editor
-
0
New Canadian distributor of Pranarōm essential oil products

For over twenty years, Pranarōm has been offering quality essential oils that have the CTEO seal of approval. CTEO stands for “Chemotyped Essential Oils”. These are guaranteed 100% pure, natural and integral. CTEO essential oils are true health vectors. In this respect, their botanic profile is scrupulously detailed and their biochemical composition has been analysed for an optimal guarantee of quality and efficacy.

Inspired by the tradition of aromatic plants and by the best of pharmacology, Pranarōm offers products containing 100% pure and natural chemotyped essential oils.

  • A range of 62 essential oils 100% pure and natural CTEO (of which 56 are certified organic)
  • A range of 18 vegetable oils (12 organic, 6 virgin)
  • A range of 5 massage selection organic oils (neutral base + 4 blends) CTEO
  • Pure organic Shea Butter
  • A range of 7 diffusion synergies (CTEO)
  • A range of 4 ultrasonic diffusers and 1 cold diffuser

Pranarōm’s expertise is well reflected in the 17 Aromavita blends for their original composition and their unique formulations are good examples of mastery and knowledge of essential oils. As of January 2015, Bio Lonreco Inc. is the exclusive Canadian distributor of the Pranarōm essential oil products. Detailed product catalogues and price list are available upon request.

For Professional Use Only.

www.biolonreco.ca

Tel: 1.800.361.6663 | 514.631.6627

Vitapath Opens on e-Street

By
Editor
-
0
Vitapath Opens on e-Street

Vitapath™, a subsidiary of U.S. based Vitamin Shoppe, Inc., recently launched its e-commerce site, Vitapath.ca. Consumers across Canada now have access to Vitapath’s broad assortment of more than 6,000 products with the ease of online shopping.

Vitapath currently operates 3 stores in the Greater Toronto Area, and with the introduction of the e-commerce option, health enthusiasts nationwide are now able to benefit from Vitapath’s great offerings. Vitapath.ca is easy to navigate with the ability to shop by category, health concern or specific brand.

“Vitapath greatly cares about the health and wellness of Canadians and we continue to work to inspire healthy living,” stated Musab Balbale, Vice President of International Development, Vitamin Shoppe, Inc. “We are excited to launch Vitapath.ca, the next step in bringing more than 6,000 products from over 300 brands to like-minded Canadians.”

Vitapath.ca offers competitive pricing and free shipping on any order $50 or more within Canada.* Additionally, orders placed before noon Eastern Time will conveniently ship out same-day.

Easton Pharmaceuticals Clinches Distribution Deal with NutraShop

By
Editor
-
0
Easton Pharmaceuticals Clinches Distribution Deal with NutraShop

Easton Pharmaceuticals Inc. has executed a distribution and intellectual property agreement for its full range of OTC therapeutic and specialty products with NutraShop Global Stores, Inc. currently serving thousands of trusting online customers looking for Quality Life Wellness Products.

Serving an online customer base who are searching for high quality wellness products NutraShop Global Stores have established strong distribution channels that allow the company to sell household specialty brands for less. Many of the products sold online can also be found in major health and grocery stores across the US and Canada, including Wholefoods and Loblaws. NutraShop is currently one of only 2 online retailers to sell the fast-emerging MadeGood Foods brand.

With the push to look better, feel better and live longer healthier lives, NutraShop now features Easton’s new line of wellness products including a cosmetic grade anti-aging serum, pain relief gel and a female health product.

In addition to distributing Easton’s OTC proprietary therapeutic products, Nutrashop has acquired rights and access to Easton’s transdermal delivery system and formulations that are to be utilized in new products being jointly developed, one of which includes a new children’s topical product containing exotic active ingredients to treat certain skin conditions.

NutraShop will compliment their existing road show by highlighting Eastons products over the next two months at the highly anticipated Yoga Show, Health Show and Mom Show throughout the greater Toronto region and upcoming U.S trade shows reaching audiences up to 125,000 looking for natural safe ways to improve health and vitality as well as new possible retail distribution channels.

Carla Pepe, CEO of Easton Pharmaceuticals, stated, “Our new distribution agreement firmly puts our products on the map alongside several already established household brand names. This partnership will set the wheels in motion for the long awaited launch and sales of our OTC and therapeutic products as we showcase our products to customers looking for effective natural solutions online in the US and Canada.”

Salmonella and Listeria Scares Trigger Recalls

By
Editor
-
0
Salmonella and Listeria Scares Trigger Recalls

It began March 17th with an array of Simply Organic and Frontier seasonings, broths and mixes containing garlic powder. The product was recalled from a number of retailers including Loblaws and Sobey’s. Salmonella usually shows up with classic food poisoning symptoms like diarrhea and abdominal cramps and can be fatal – but no cases of illness have been reported to date.

Samonella concerns continued this week with Aurora Products Inc. recalling their trail mix because of the possibility of contaminated walnuts. The major retailers involved include Giant Food Stores and Stop and Shop stores in the US, as well as Aurora Cranberry Health Mix sold at Winners, HomeSense and Marshalls in Canada.

As if that weren’t enough; a variety of Amy’s Kitchen natural and organic frozen food products are being recalled from Canadian and US retailers for possible listeria contamination. Listeria symptoms include fever, headache and nausea – appearing up to 70 days after infection. While seldom fatal, listeria can cause miscarriages and stillbirth in pregnant women. Unlike most other bacteria, listeria can grow and spread to other foods in your refrigerator. Recalled items can be returned to the stores where they were purchased for a refund.

Neptune Locks Down Patents

By
Editor
-
0
Nestle under pressure as Maggi withdrawn from shelves

Neptune Technologies & Bioressources Inc. and Acasti Pharma Inc. announced that on March 23, 2015 the Patent Trial and Appeal Board (PTAB) of the US Patent and Trademark Office (USPTO) issued a favourable decision, confirming the validity of certain claims in Neptune’s ‘351 patent
(U.S. Patent: 8,278,351) and impelling royalty payments to Neptune.

“This is a significant milestone that triggers the payment of ongoing royalties to Neptune by Aker and Enzymotec, based on their sales of licensed krill oil products in the US,” highlighted Jim Hamilton, President and CEO of Neptune. “The decision clearly supports the validity and enforceability of Neptune’s ‘351 composition of matter patent. Now that the positive decision has been rendered, we can turn our attention to building the industry and growing the krill oil market.”

“Our intellectual property (IP) is a fundamental and valuable asset,” highlighted Benoit Huart, Director Legal Affairs at Neptune. “The positive decision preserves strong IP protection for both our nutraceutical and pharmaceutical businesses and substantiates our IP procurement and enforcement strategy. Aker and Enzymotec may appeal the decision. Regardless, the strength of our patent estate has once again been recognized. We will continue to enforce and build upon it to ensure we have long lasting and comprehensive protection, while preventing others from importing into and selling infringing products wherever we have valid patents.”

On December 17, 2013, Neptune announced that it had successfully concluded a settlement and license agreement with Aker and on April 27, 2014, they completed one with Enzymotec. Neptune granted a world-wide, non-exclusive, royalty-bearing license to both parties to market and sell nutraceutical products in the licensed countries. Pursuant to the terms of these settlements, royalty levels in the US depended on the outcome of an inter parties review at the PTAB of certain claims from Neptune’s ‘351 patent. In light of the PTAB’s decision, Aker and Enzymotec will be obligated to make royalty payments to Neptune based on their sales of licensed krill oil products in the US. Under the terms of the settlement agreement with Enzymotec, their royalty obligations in Australia were similarly dependent on the outcome of a potential request with the Australian Patent Office for a review of certain claims. A patent reexamination recently commenced.

On March 24th, Neptune announced that the Chinese Patent Office has granted Acasti a composition and use patent – valid until 2030 – relating to concentrated therapeutic phospholipid omega-3 compositions and covering methods for treating or preventing diseases associated with cardiovascular diseases, metabolic syndrome, inflammation, neurodevelopmental diseases, and neurodegenerative diseases. “To date, Acasti has received patents in the United States, Australia, Panama and South Africa for its phospholipid composition,” highlighted Benoit Huart, Director Legal Affairs at Acasti. “As well, similar patent applications are pending in more than 40 jurisdictions worldwide and are actively being pursued. This is yet another example of our commitment to build and extend our patent estate.”

“Today’s announcement further enhances the value of our intellectual property, by protecting a vast market and providing potential expansion opportunities for Acasti’s products going forward,” said Pierre Lemieux, PhD, Acasti’s Chief Operating Officer. “There is a large unmet need for high-quality, well-studied and differentiated krill products in China. It is the third largest pharmaceutical market in the world, with an average compound annual sales growth rate of approximately 20% over the past ten years.”

1...270271272...388Page 271 of 388

EDITOR PICKS

POPULAR POSTS

POPULAR CATEGORY

© 2026 IHR Magazine | Canada's Natural Health Industry Authority | Le guide de l’industrie canadienne de la santé naturelle